

References

1. **Abd El Mohsen MM, Kuhnle G, Rechner AR, et al., (2002):** Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. *Free Radic Biol Med.* 33:1693–702.
2. **Abdelmoaty a,c, M A Ibrahim b,d, N S Ahmed a,c and M Abdelaziz., (2010):** Confirmatory studies on the antioxidant and anti-diabetic effect of Quercetin in rats. *Indian Journal of Clinical Biochemistry*, 2010 / 25 (2) 188-192.
3. **Abigail J. Larson 1, J. David Symons 1, and Thunder Jalili (2010):** Quercetin: A Treatment for Hypertension—A Review of Efficacy and Mechanisms *Pharmaceuticals*, 3, 237-250.
4. **Ahmed RG., (2005):** The physiological and biochemical effects of diabetes on the balance between oxidative stress and antioxidant defense system. *Med J Islamic World Acad Sci*; 15:31-42.
5. **Ahrén, B. (1998):** Glucagon-like peptide 1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes. *BioEssays* 20, 642-651.
6. **Alexandre Simões Dias, Marilene Porawski, Mari'a Alonso, Norma Marroni, Pilar S. Collado, and Javier González-Gallego J. Nutr. (2005):** Quercetin Decreases Oxidative Stress, NF- κ B Activation, and iNOS Overexpression in Liver of Streptozotocin-Induced Diabetic Rats *Nutr.* 135: 2299–2304.

7. **Allan D. Coldiron Jr., Ruth A. Sanders, and John B. Watkins., (2002):** Effects of Combined Quercetin and Coenzyme Q10 Treatment on Oxidative Stress in Normal and Diabetic Rats. Medical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana 47405-7005.
8. **Ametov AS, Barinov a, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, and O'Brien PC., (2003):** The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. *Diabetes Care*; 26:770-776.
9. **ANJANEYULU M, CHOPRA K., (2004):** Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. *Clin Exp Pharmacol Physiol* 31: 244-248
10. **Ansari, MA et al. (2008):** Protective effect of Quercetin in primary neurons against A β (1-42): relevance to Alzheimer's disease. *Journal of Nutritional Biochemistry*. Article in press.
11. **Babior BM, Lambeth JD, Nauseef W (2002):** The neutrophil NADPH oxidase. *Arch Biochem Biophys* 397:342–344, pmid: 11795892.
12. **Babior BM., (2000):** The NADPH oxidase of endothelial cells. *IUBMB Life* 50:267–269, pmid: 11327320.
13. **Baillie, J K; A A R Thompson, J B Irving, M G D Bates, A I Sutherland, W Macnee, S R J Maxwell, D J Webb (2009):** Oral antioxidant supplementation does not prevent acute mountain

- sickness: double blind randomized placebo-controlled trial. 102 (5): 341–8.
- 14.**Balazs, L and M. Leon (1994):** Evidence of an oxidative challenge in the Alzheimer’s brain. *Neurochemical Research* 19: 1131-1137.
- 15.**Baumann, C. A., Ribon, V., Kanzaki, M., Thurmond, D. C., Mora, S., Shigematsu, S., Bickel, P. E., Pessin, J. E., and Saltiel, A. R. (2000):** Lipid rafts are required for GLUT4 internalization in adipose cells. *Nature* 407(6801), 202-207.
- 16.**Baynes J., Dominiczak M., (2004):** Glucose homeostasis and fuel metabolism. *Medical Biochemistry*; 2 ed. 243-266.
- 17.**Baynes JW, Thorpe SR (1999):** Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. *J. of Diabetes*, 1999; 48: 1 - 9.
- 18.**Baynes W., (2003):** Chemical modification of protein by lipids in diabetes. *Clin Chem Lab Med.*; 41:1159-1165.
- 19.**Beecher, GR (2003):** Overview of dietary flavonoids: nomenclature, occurrence and intake. *The Journal of Nutrition* 133: 3248S-3254S.
- 20.**Bergman, R. N., and Ader, M. (2000):** Trends *Endocrinol Metab* 11(9), 351-356
- 21.**Bernard-Kargar, C. and Ktorza, A. (2001):** Endocrine pancreas plasticity under physiological and pathological conditions. *Diabetes*, 50: 30S–35S.

-
- 22.**Bhattaram VA, Graefe U, Kohlert C, et al., (2002):** Bioavailability and Pharmacokinetics of Alkamides from the Roots of *Echinacea angustifolia* in Humans J. Clin. Pharmacol., ; 45: 683 – 689
- 23.**Binda, C.R. Molinas and P.R. Koninckx., (2003):** Reactive oxygen species and adhesion formation Clinical implications in adhesion prevention Human Reproduction, Vol. 18, No. 12, 2503-2507.
- 24.**Bjelakovic G; Nikolova, D; Gluud, LL; Simonetti, RG; Gluud, C (2007):** Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.
- 25.**Boaz M, Smetana S, Weinstein T, Matas Z, Gafer U, Iaina a, Knecht a, Weissgarten Y, Brunner D, et al., (2000):** Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) randomized placebo-controlled trial. Lancet. 356:1213-1218.
- 26.**Boden, G, Chen, X, Ruiz, J, White, JV, and Rosetti, L (1994):** Mechanism of fatty acid induced inhibition of glucose uptake. J Clin Invest. 93:2438-2446.
27. **Boothby LA, Doering PL., (2005):** Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39 (12): 2073–80.
- 28.**Boots, AW et al., (2008):** In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24: 703-710.
- 29.**Bouktaib, M et al., (2002):** Regio- and stereoselective synthesis of the major metabolite of quercetin, quercetin-3-O-b-D-glucuronide. Tetrahedron Letters 43: 6263-6266.
-

-
- 30.**Buse JB, Weyer C and Maggs D., (2002):** Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. *Clinical Diabetes* 20:137–144.
- 31.**Butler AE, Janson J, Bonner-Weir S, et al., (2002):** Decreased B-cell mass in patients with type 2 diabetes. June 14-18, Poster 1502-P. *Diabetes*, Volume 51, Supplement 2.
- 32.**C. Catena, R. Lapenna, S. Baroselli, and et al., (2006):** Insulin sensitivity in patients with primary aldosteronism: a follow-up study, *Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 9, p p. 3457–3463.
- 33.**Carvalho, K. Kotani, O. D. Peroni, and B. B. Kahn (2005):** Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle,” *American Journal of Physiology*, vol. 289, no. 4, pp. E551–E561.
- 34.**Ceriello A., (2000):** Oxidative stress and glycemic regulation. *Metabolism.* ; 49:27-29.
- 35.**Chan Hun Jung, Ji Yun Lee, Chul Hyung Cho, and Chang Jong Kim., (2007):** Anti-asthmatic Action of Quercetin and Rutin in Conscious Guinea-pigs Challenged with Aerosolized Ovalbumin *Arch Pharm Res* Vol 30, No 12, 1599-1607.
- 36.**Chan MM, Mattiacci JA, Hwang HS, et al., (2000):** Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. *Biochem Pharmacol* ; 60: 1539–1548.

- 37.**Chiang, S. H., Baumann, C. A., Kanzaki, M., Thurmond, D. C., Watson, R. T., Neudauer, C. L., Macara, I. G., Pessin, J. E., and Saltiel, A. R. (2001)** Nature 410(6831), 944-948.
- 38.**Chiu KC, Chu a, Go VL, Saad MF (2004):** Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction". American Journal of Clinical Nutrition 79 (5): 820–825.
- 39.**Chopra, M et al. (2000):** Nonalcoholic red wine extract and Quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clinical Chemistry 46: 1162-1170.
- 40.**Chougale, A.D., S.N. Panaskar, P.M. Gurao and A.U. Arvindekar, (2007):** Optimization of alloxan dose is essential to induce stable diabetes for prolonged period. Asian J. Biochem., 2: 402-408.
- 41.**Christen Y., (2000):** Oxidative stress and Alzheimer disease. Am J Clin Nutr 71 (2): 621S–629S.
- 42.**Clancy, D. J., Gems, D., Harshman, L. G., Oldham, S., Stocker, H., Hafen, E., Leivers, S. J., and Partridge, L. (2001):** Science 292(5514), 104-106.
- 43.**Claudine Manach, Augustin Scalbert, Christine Morand, Christian Rémésy and Liliana Jiménez Polyphenols., (2004):** food sources and bioavailability¹ American Journal of Clinical Nutrition, Vol. 79, No. 5, 727-747, American Society for Clinical Nutrition.
- 44.**Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, and Hirsch IB., (2004):** Management of diabetes and hyperglycemia in hospitals. Diabetes Care; 27:553-591.

45. **Cohen, P. (2006)** Nat Rev Mol Cell Biol 7(11), 867-873
46. **Coldham NG and Sauer MJ., (2000):** Pharmacokinetics of Genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicol Appl Pharmacol; 164:206–15.
47. **Coskum O, Kanter M, Korkmaz A and Oter S., (2005):** Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β -cell damage in rat pancreas. Pharmacol Res. 51:117-123.
48. **Coskum O, Kanter M, Korkmaz A, and Oter S. (2005):** Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β -cell damage in rat pancreas. Pharmacol Res.; 51:117–23.
49. **Coussens LM and Werb Z., (2002):** Inflammation and cancer. Nature; 420: 860-7.
50. **CROLEY T. R., HUGHES R. J., METCALFE C. D and MARCH R. E., (2000):** Observation of Na⁺-bound oligomers of quercetin in the gas phase. Rapid Commun. Mass Spectrom. 14, 2154.
51. **Cryer PE (1992):** Glucose homeostasis and hypoglycaemia. In William's Textbook of Endocrinology. p. 1223–1253.
52. **Cushnie TPT, Lamb AJ (2005):** Antimicrobial activity of flavonoids. International Journal of Antimicrobial Agents 26 (5): 343–356.

- 53.**Cusi, K, et al., (2000):** Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. *J Clin Invest* 2000. 105:311-320.
- 54.**D'Alessio DA, Air EL and Woods SC (2001):** Inhibition of central amylin signaling increases food intake and body adiposity in rats. *Endocrinology* 142:5035–5038.
- 55.**Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., and Pearl, L. H. (2001) :**Cell 105(6), 721-732.
- 56.**Dangles O, Dufour C, Manach C, Morand C, Remesy C., (2001):** Binding of flavonoids to plasma proteins. *Methods Enzymol*; 335:319–33.
- 57.**Datla KP, Christidou M, Widmer WW, Rooprai HK, Dexter DT., (2001):** Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. *Neuroreport* 2001; 12:3871–5
- 58.**Davì G, Falco A, Patrono C., (2005):** Lipid peroxidation in diabetes mellitus. *Antioxid Redox Signal* 7 (1–2): 256–68.
- 59.**De Boer V, et al., (2005):** Tissue distribution of Quercetin in rats and pigs. *J Nutr*; 1718-25.
- 60.**De Diego-Otero Y, Romero-Zerbo Y, el Bekay R, Decara J, Sanchez L, Rodriguez-de Fonseca F, del Arco-Herrera I. (2009):** Alpha tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. *Neuropsychopharmacology* 34 (4): 1011–26.

- 61.**De Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV, Aoyama H. (2007):** Phosphoprotein levels, MAPK activities and NFkappaB expression are affected by fisetin. *J Enzyme Inhib Med Chem* 22 (4): 439–444.
- 62.**Defeng Wu, Ph.D., and Arthur I. Cederbaum, (2003):** Alcohol, Oxidative Stress, and Free Radical Damage Ph.D. Vol. 27, No. 4,
- 63.**DENE BA, MARITIM AC, SANDERS RA, WATKINS JB., (2005):** Effects of antioxidant treatment on normal and diabetic rat retinal enzyme activities. *J Ocular Pharmacol Ther* **21**: 28-35
- 64.**Drucker DJ (2003):** "Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis". *Mol. Endocrinol.* 17 (2): 161–71.
- 65.**Drucker DJ, (2001):** the glucagon-like peptides. *Endocrinology* 142: 521–527.
- 66.**Dunnick JK and Hailey JR., (1992):** Toxicity and carcinogenicity studies of quercetin, a natural component of foods. *Fundam Appl Toxicol* 19:423–31.
- 67.**Edgerton, DS, Lautz, M, Scott, M, et al., (2006):** Insulin's direct effects on the liver dominate the control of hepatic glucose production. *J Clin Invest* 116:521.
- 68.**Egert, S.; Wolfram, S.; Bosy-Westphal, A., (2008):** Boesch-Saadatmandi, C.; Wagner, A.E.; Frank, J.; Rimbach, G.; Mueller, M.J. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. *J. Nutr.*, 138, 1615–1621.

-
- 69.**Erden Inal M and Kahraman A., (2000):** The protective effect of flavonol quercetin against ultraviolet A induced oxidative stress in rats. *Toxicology*;154:21-29.
- 70.**Evans JL, Goldfine ID, Maddux BA and Grodsky GM., (2002):** **Oxidative** stress-activated signaling pathways: a unifying hypothesis type 2 diabetes. *Endocr Rev.*; 23:599–622.
- 71.**Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, (2002):** Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes, *Endocrine Reviews*, vol. 23, no. 5, pp. 599–622.
- 72.**Farmer A, Wade A, Goyder E, et al. (2007):** Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial.
- 73.**Florez H, Castillo-Florez S and Mendez A., (2005):** C-reactive protein is elevated in obese patients with the metabolic syndrome. *Diabetes Res Clin Pract.*
- 74.**Forman, H.J. and Torres, M., (2002):** Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. *Am. J. Respir. Crit. Care Med.*, 166, S4–S8
- 75.**Formica JV and Regelson W., (1995):** Review of the biology of Quercetin and related bioflavonoids. *Food Chem Toxicol*; 33: 1061–1080.
- 76.**Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., and Vigneri, R. (1999):** *Mol Cell Biol* 19(5), 3278-3288
-

-
77. **Gaede P, Poulsen HE, Parving HH and Pedersen O., (2001):** Double-blind, randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. *Diabet Med.*; 18:756–60.
78. **Galeotti, F; Barile, E; Curir, P; Dolci, M; Lanzotti, V., (2008):** Flavonoids from carnation (*Dianthus caryophyllus*) and their antifungal activity. *Phytochemistry Letters* 1: 44.
79. **Garlid, K. D., Jaburek, M., & Jezek, P. (2001).** Mechanism of uncoupling protein action. *Biochemical Society Transactions* 29, 803-806.
80. **Gebhardt R., (2003):** Variable influence of kaempferol and myricetin on in vitro hepatocellular cholesterol biosynthesis. *Planta Med*; 69(12):1071-4.
81. **Geleijnse, J.M.; Launer, L.J.; Van der Kuip, D.A.; Hofman, A. and Witteman, J.C. (2002):** Inverse association of tea and flavonoid intakes with incident myocardial infarction: The Rotterdam Study. *Am. J. Clin. Nutr.* 75, 880–886.
82. **Gerich, J. E. (2002):** Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? *Diabetes* 51 Suppl 1, S117-S121.
83. **Giugliano D, Ceriello A, Paolisso G (1996):** Oxidative stress and diabetic vascular complications. *Diabetes Care* 19 (3): 257–67.
84. **Goldfine, I. D., Maddux, B. A., Youngren, J. F., Trischitta, V., and Frittitta, L. (1999)** *Ann N Y Acad Sci* 892, 204-222.
-

-
- 85.**Gorogawa, Y. Kajimoto, Y. Umayahara, et al., (2002):** Probucol preserves pancreatic β -cell function through reduction of oxidative stress in type 2 diabetes. *Diabetes Research and Clinical Practice*, vol. 57, no. 1, pp. 1–10.
- 86.**GOUTHAM RAO, (2001):** University of Pittsburgh Medical Center–St. Margaret, Pittsburgh, Pennsylvania *Am Fam Physician*. Mar 15; 63 (6):1159-1164. Insulin Resistance Syndrome
- 87.**Graf, B et al., (2005):** Flavonols, flavones, flavanones, and human health: epidemiological evidence. *Journal of Medicinal Food* 8: 281-290
- 88.**Grassme, H., S. Kirschnek, J. Riethmueller, A. Riehle, G. von Kurthy, F. Lang, M. Weller, and E. Gulbins. (2000):** ligand interactions on epithelial cells in host defense to *Pseudomonas aeruginosa*. *Science* 290: 527-530.
- 89.**Greco, A. V., Mingrone, G., Giancaterini, A., Manco, M., Morroni, M., Cinti, S., Granzotto, M., Vettor, R., Camastra, S., and Ferrannini, E. (2002)** *Diabetes* 51(1), 144-151.
- 90.**Grobbee DE., (2003):** How to advance prevention of cardiovascular complications in type 2 diabetes *Metabolism*; 52:24-28.
- 91.**Haber, T. K. T. Lam, Z. Yu, et al., (2003):** N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress,” *American Journal of Physiology*, vol. 285, no. 4, pp. E744–E753.
- 92.**Halliwell B., (1997):** Antioxidants: the basics–what they are and how to evaluate them. *Adv Pharmacol* 38:3-19.
-

- 93.**Hancock, R. Desikan and S. J. Neill., (2001):** Role of reactive oxygen species in cell signalling pathways Biochemical Society Transactions, Volume 29, part 2.
- 94.**Harwood M.; Danielewska-Nikiel B.; Borzellaca J.F.; Flamm G.W.; Williams G.M. and Lines T.C. A (2007):** Critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 45, 2178-2205.
- 95.**Hayes J, Flanagan J, Jowsey I., (2005):** Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51–88.
- 96.**Henquin, J. C., Ishiyama, N., Nenquin, M., Ravier, M. A., and Jonas, J. C., (2002):** Signals and pools underlying biphasic insulin secretion. Diabetes 51, Suppl 1, S60-S67.
- 97.**Hertog MG and Hollman PC., (1996):** Potential health effects of the dietary flavonol quercetin. Eur J Clin Nutr; 50: 63–71.
- 98.**Hideaki Kaneto, Naoto Katakami, Munehide Matsuhisa, and Taka-aki Matsuoka ., (2010):** Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis Mediators of Inflammation. Volume 2010, Article ID 453892.
- 99.**Hitchon C, El-Gabalawy H (2004):** Oxidation in rheumatoid arthritis. Arthritis Res Ther 6 (6): 265–78.
100. **Hitchon C, El-Gabalawy H (2004):** Oxidation in rheumatoid arthritis. Arthritis Res Ther 6 (6): 265–78.

101. **Hollman PCH, Devries JHM, Vanleeuwen SD, Mengelers MJB, Katan MB., (1995):** Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. *Am J Clin Nutr*; 62:1276–82.
102. **Hollman, P.C.; vd Gaag, M.; Mengelers, M.J.; van Trijp, J.M.; de Vries, J.H.; Katan, M.B., (1996):** Absorption and disposition kinetics of the dietary antioxidant quercetin in man. *Free Radic. Biol. Med.*, 21, 703–707.
103. **Hollman, PCH and M.B. Katan (1997):** Absorption, metabolism and health effects of dietary flavonoids in man. *Biomed. & Pharmacother.* 51: 305-310.
104. **Hollman, PCH et al., (1996):** Analysis and health effects of flavonoids. *Food Chemistry* 57: 43-46.
105. **Honda, S., Hjelmeland, L.M. and Handa, J.T., (2002):** Senescence associated beta galactosidase activity in human retinal pigment epithelial cells exposed to mild hyperoxia in vitro. *Br. J. Ophthalmol.*, 86, 159–162.
106. **Hruz P and Mueckler M (2001):** "Structural analysis of the GLUT1 facilitative glucose transporter (review)". *Mol. Membr. Biol.* 18 (3): 183–93.
107. **Huang YT, Hwang JJ, Lee PP, et al. (2010):** Effects hypoglycemic effects of onion and garlic in alloxan–induced diabetic Insulin Helps Fat Storage: Insulin Effects on Lipid Metabolism Lakshmi Ananth.

-
108. **Igura K, Ohta T, Kuroda Y, and Kaji K., (2001):** Resvetatrol and quercetin inhibit angiogenesis in vitro. *Cancer Lett.* ; 171:11-16
109. **Inal ME, Akgun A, Kahraman A., (2002):.** Radioprotective effects of exogenous glutathione against whole-body gamma-ray irradiation: age and gender-related changes in malondialdehyde levels, superoxide Dismutase and catalase activities in rat liver. *Methods Find Exp Clin*
110. **Inoguchi, P. Li, F. Umeda, et al., (2000):** High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C—dependent activation of NAD(P)H oxidase in cultured vascular cells, *Diabetes*, vol. 49, no. 11, pp. 1939–1945.
111. **Jacob, P. Ruus, R. Hermann, et al.,(1999):** “Oral administration of rac- α -lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial,” *Free Radical Biology and Medicine*, vol. 27, no. 3-4, pp. 309–314, 1999.
112. **Janisch KM, Williamson G, Needs P and Plumb GW., (2004):** Properties of Quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. *Free Radic Res*; 38: 877–884.
113. **Janisch, KM et al. (2004):** Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. *Free Radical Research* 38: 877-884.
114. **Jeff Unger, (2008):** "Intensive Management of Type 2 Diabetes". *Emergency Medicine*. Retrieved 01-13.

-
115. **Jeffrey E. Pessin and Alan R. Saltiel., (2000):** Signaling pathways in insulin action: molecular targets of insulin resistance. Volume 106, Issue 2, J Clin Invest. ; 106(2):165–169.
116. **Jens C. Bruning, Dinesh Gautam, Deborah J. Burks, Jennifer Gillette, Markus Schubert, Paul C. Orban,3 Rudiger Klein, Wilhelm Krone, Dirk Muller-Wieland and C. Ronald Kahn, (2000):** Role of Brain Insulin Receptor in Control of Body Weight and Reproduction VOL 2122 289 SCIENCE
117. **Jiang, J. S., Shih, C. M., Wang, S. H., Chen, T. T., Lin, C. N., and Ko, W. C., (2006):** Mechanisms of suppression of nitric oxide production by 3-O-methylquercetin in RAW 264.7 cells. J. Ethnopharmacol., 103, 281-287.
118. **John Dupre., (2002):** Type 1 Diabetes Prevention Diabetes & Endocrinology April, 2002
119. **Julio F Turrens., (2003):** Mitochondrial formation of reactive oxygen species J Physiol, 552 (2) 335-344.
120. **Kahn, S. E. (2003):** The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46, 3-19.
121. **Kaiser, N., Leibowitz, G. and Nesher, R. (2003):** Glucotoxicity and β -cell failure in type 2 diabetes mellitus. J. Pediat. Endocrinol. Metab., 16: 5–22.
122. **Kanter M, Meral I, Dede S, Gunduz H, Cemek M, and Ozbek H., (2003):** Effects of *Nigella sativa* L. and *Urtica dioica* L. on lipid peroxidation, antioxidant enzyme systems and some liver enzymes in
-

- CCL₄-treated rats, J Vet Med A Physiol Pathol Clin Med 2003; 50: 264-8.
123. **Kanter M, Meral I, Dede S, Gunduz H, Cemek M, and Ozbek H., (2003):** Effects of *Nigella sativa* L. and *Urtica dioica* L. on lipid peroxidation, antioxidant enzyme systems and some liver enzymes in CCL₄-treated rats, J Vet Med A Physiol Pathol Clin Med 2003; 50: 264-8.
124. **Kathleen M. Gillespie (2006):** Type 1 diabetes: pathogenesis and prevention. CMAJ (2). doi:10.1503/cmaj.060244.
125. **Kim HP et al., (1998):** Effects of naturally-occurring flavonoids on epidermal cyclooxygenase from guinea pigs. Prostaglandins Leukot Essent Fatty Acids 1998; 58:17.
126. **Kim, J. K., Fillmore, J. J., Chen, Y., Yu, C., Moore, I. K., Pypaert, M., Lutz, E. P., Kako, Y., Velez-Carrasco, W., Goldberg, I. J., Breslow, J. L., and Shulman, G. I. (2001)** Proc Natl Acad Sci U S A 98(13), 7522-7527
127. **King GL and Loeken MR., (2004):** Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol.; 122:333–8.
128. **Knekt P, et al., (2002):** Flavonoid intake and risk of chronic diseases. Am J Clin Nutr ; 76:560-8.
129. **Knekt P, Jarvinen R, Seppanen R, et al., (1997):** Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiology; 146:223–30.

130. **Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T and Aromaa A (2002):** Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr* 76: 560-568
131. **KNEKT P, KUMPULAINEN J, JÄRVINEN R, RISSANEN H, HELIÖVAARA M, REUNANEN A, HAKULINEN and T, AROMAA A (2002):** Flavonoid intake and risk of chronic diseases. *Am J Clin Nutr* 76: 560-568.
132. **Ko W. C. Chen M. C. Wang S. H. Lai Y. H. Chen J. H. and Lin C. N., (2003):** 3-O-methylquercetin more selectively inhibits phosphodiesterase subtype 3. *Planta Med.*, 69, 310-315.
133. **Kontush K, Schekatolina S (2004):** Vitamin E in neurodegenerative disorders: Alzheimer's disease. *Ann. N. Y. Acad. Sci.* 1031: 249–62.
134. **Korkina LG and Afanas'ev IB., (1997):** Antioxidant and chelating properties of flavonoids. *Adv Pharmacol*; 38:151–63.
135. **Kowluru RA, and Chan PS., (2007):** Oxidative stress and diabetic retinopathy. *Exp Diabetes Res.* :43603.
136. **Kowluru RA., (2003):** Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. *Diabetes.* 52:818-823.
137. **Kruger DF, Gatcomb PM and Owen SK., (1999):** Clinical Implications of amylin and amylin deficiency. *Diabetes Educ* 25:389–397.

138. **KUO S. M., LEAVIT P. S., LIN C. P., (1998):** Dietary flavonoids interact with trace metals and affect metallothionein level in human intestinal cells. *Biol. Trace Elem. Res.* 62, 135.
139. **Lee, H. C., Kim, S. J., Kim, K. S., Shin, H. C., & Yoon, J. W., (2000):** Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. *Nature* 408, 483-488.
140. **Liochev SI and Fridovich I., (1999):** Superoxide and iron: partners in crime. *IUBMB Life* 48:157–161, pmid: 10794591.
141. **Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zimman B, Bosch J, Dagenais G, Mann J, Gerstein H. C., (2002):** Effects of vitamin E on cardiovascular and microvascular outcomes in high risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. *Diabetes Care.* 25:1919-1927.
142. **Lopez-Soriano J, Chiellini C, Maffei M, Grimaldi PA and Argiles JM.,(2006):** Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. *Endocr Rev* 27: 318–329.
143. **Louvi, A., Accili, D., and Efstratiadis, A., (1997):** *Dev Biol* 189(1), 33-48
144. **Ludwig, D. S. (2002):** The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. *JAMA* 287, 2414-2423
145. **LUKAČÍNOVÁ, J. MOJŽIŠ, R. BEŇAČKA, J. KELLER, T. MAGUTH, P. KURILA, L. VAŠKO, O. RÁ CZ, F. NIŠTIAR., (2008):** Preventive Effects of Flavonoids on Alloxan-Induced

- Diabetes Mellitus in Rats. *Pharmacological Research* 51 (2005) 117–123
- Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and B-cell damage in rat pancreas.
146. **MAGHRANI M, MICHEL JB, EDDOUKS M (2005):** Hypoglycaemic activity of Retama raetam in rats. *Phytother Res* 19: 125-128
 147. **Mahesh T and Menom VP., (2004):** Quercetin alleviates oxidative stress in streptozotocin- induced diabetic rats. *Phytother Res.*; 18:123–7.
 148. **Mahesh T, Menom VP, (2004):** Quercetin alleviates oxidative stress in streptozotocin-induced diabetic rats. *Phytother Res.*; 18:123.
 149. **Marchioli R, Scweiger C, Levantesi G, Gavazzi L, Valagussa F.** Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. *Lipids.* 2001;36:S53–65.
 150. **Marchioli R, Scweiger C, Levantesi G, Gavazzi L, Valagussa F., (2001):** Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. *Lipids.* 36:S53-S65.
 151. **Maritim AC, Sanders RA, Watkins III JB., (2003):** Effects of α -lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetics rats. *J Nutr Biochem.*; 14:288–94.
 152. **Masri FA, Comhair SA, Koeck T, et al., (2005):** Abnormalities in nitric oxide and its derivatives in lung cancer. *Am J Respir Crit Care Med*; 172: 597-605.

-
153. **McGarry J (2002):** "Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes". *Diabetes* 51 (1): 7–18.
154. **McManus LM, Bloodworth RC, Prihoda TJ, Blodgett JL, Pinckard RN., (2001):** Agonist-dependent failure of neutrophil function in diabetes correlates with extent of hyperglycemia. *J Leukoc Biol.*; 70:395-404.
155. **Meier J, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck M, Holst J, Schmidt W and Gallwitz B., (2004):** Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. *Crit Care Med* 32 (3): 848–51.
156. **Mertens-Talcott SU, and Percival SS., (2005):** Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. *Cancer Lett* 218: 141–151.
157. **Michael R. Peluso., (2006):** Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver *Exp. Biol. Med.*; 231:1287-1299.
158. **Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., and Kahn, C. R. (2000):** *Mol Cell* 6(1), 87-97.
159. **Middleton J., (1998):** Effect of plant flavonoids on immune and inflammatory cell function. *Adv. Exp. Med. Biol.*; 439: 175-82.
160. **Middleton. (1998):** Effect of plant flavonoids on immune and inflammatory cell function. *Adv Exp Med Biol*; 439:175–82.
-

161. **Milagro FI and Martínez JA., (2000):** Effect of the oral administration of a beta3- adrenergic agonist on lipid metabolism in alloxan-diabetic rats. *J Pharm Pharmacol*.
162. **Miller CM and Kern TS., (2003):** Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. *Free Radic Biol Med.*; 35:1491-1499.
163. **Miller, A. L. (1996):** Antioxidant flavonoids: structure, function and clinical usage. *Alt. Med. Rev.*, 1: 103–111.
164. **Moller, D. E. (2001):** New drug targets for type 2 diabetes and the metabolic syndrome. *Nature* 414, 821-827.
165. **Moore, G. B. T., Himms-Hagen, J., Harper, M. E., & Clapham, J. C. (2001):** Overexpression of UCP-3 in skeletal muscle of mice results in increased expression of mitochondrial thioesterase mRNA. *Biochemical and Biophysical Research Communications* 283, 785-790.
166. **Mu MM, Chakravortty D, Sugiyama T, et al., (2001):** The inhibitory action of quercetin on lipopolysaccharideinduced nitric oxide production in RAW 264.7 macrophage cells. *J Endotoxin Res* 2001; 7:431–438.
167. **Mullen W., Graf B. A., Caldwell S. T., Hartley R. C., Duthie G. G., Edwards C. A., Lean M. E., Crozier A., (2002):** Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4'-glucoside. *J. Agric. Food Chem.*; 50:6902-6909.

-
168. **Mullen, W., Boitier, A., Stewart, A. J. and Crozier, A., (2004):** Flavonoid metabolites in human plasma and urine after the consumption of red onions: analysis by liquid chromatography with photodiode array and full scan tandem mass spectrometric detection. *J. Chromatogr. A* 1058, 163–168.
169. **Muller FL, Lustgarten MS, Jang Y, Richardson A and Van Remmen H (2007):** Trends in oxidative aging theories. *Free Radic. Biol. Med.* 43 (4): 477–503.
170. **Murota, K and J. Terao (2003):** Antioxidative flavonoid quercetin: implications of its intestinal absorption and metabolism. *Archives of Biochemistry and Biophysics* 417: 12-17.
171. **Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ and Hellstrom PM, (1999):** GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. *Am J Physiol* 277:R910–R916.
172. **Nauck, M. A. (1998):** Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective. *Acta Diabetologica* 35, 117-129.
173. **Neely KA, Quillen DA, Schachat AP, Gardner TW and Blankenship GW, (1998):** Diabetic retinopathy. *Med Clin North Am*; 82:847-876.
174. **Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M.,(2000):** Normalizing mitochondrial superoxide

- production blocks three pathways of hyperglycaemic damage. *Nature* 404: 787-790.
175. **Notkins, A. L. (2002):** Immunologic and genetic factors in type 1 diabetes. *Journal of Biological Chemistry* 277, 43545-43548
 176. **Nunomura A, Castellani R, Zhu X, Moreira P, Perry G, Smith M (2006):** Involvement of oxidative stress in Alzheimer disease. *J Neuropathol Exp Neurol* 65 (7): 631–41.
 177. **O’Rahilly, (1997):** S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. *BMJ*. 314:955-959.
 178. **Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, and Ohta S., (2007):** Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med.*; 13:688-694.
 179. **Omer Coskun a, Mehmet Kanter a, Ahmet Korkmaz b, Sukru Oter b., (2005):** Quercetin, a flavonoid antioxidant, prevents and protects
 180. **Pan DA. et al., (1997):** Skeletal muscle triglyceride levels are inversely related to insulin action. *Diabetes*. 46:983-988.
 181. **Paul S. MacLean, Zheng, D; Jones, JP; Olson, AL and Dohm, GL (2002):** Exercise-Induced Transcription of the Muscle Glucose Transporter (GLUT 4) Gene. *Biochemical and Biophysical Research Communications* 292 (2): 409–414

-
182. **Pedersen BK, Akerstrom TCA, Nielsen AR and Fischer CP (2007):** Role of myokines in exercise and metabolism. *J Appl Physiol* 35: 1295–1297.
183. **Pelicano H, Carney D, and Huang P., (2004):** ROS stress in cancer cells and therapeutic implications. *Drug Resist Update*; 7: 97-110.
184. **Perez-Vizcaino F, Duarte J, Andriantsitohaina R., (2006):** Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. *Free Radic Res.*; 40(10):1054-65.
185. **Perseghin, G, Ghosh, S, Gerow, K, Shulman, GI. (1997):** Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. *Diabetes*. 46:1001-1009
186. **Pignatelli B, Li CQ, Boffetta P, et al., (2001):** Nitrated and oxidized plasma proteins in smokers and lung cancer patients. *Cancer Res*; 61: 778-84.
187. **Prabhakar S, Starnes J, Shi S, Lonis B and Tran R., (2007):** Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. *J Am Soc Nephrol.* ; 18:2945-2952.
188. **Price SF, Breen PJ, Valladao M and Watson BT., (1995):** Cluster sun exposure and quercetin in Pinot noir grapes and wine. *Am J Enol Vitic*;46:187–94.
189. **Pryor WA (2000):** Vitamin E and heart disease: basic science to clinical intervention trials. *Free Radic. Biol. Med.* 28 (1): 141–64.

190. **Rada B and Leto TL., (2008):** Oxidative innate immune defenses by Nox/Duox family NADPH oxidases *Contrib Microbiol* 15: 164–87.
191. **Radi R, Cassina A, Hodara R, Quijano C, Castro L., (2002):** Peroxynitrite reactions and formation in mitochondria. *Free Radic Biol Med* 33:1451–1464, pmid: 12446202.
192. **Rajagopal K, Sasikala K., (2008):** Antihyperglycaemic and antihyperlipidaemic effects of *Nymphaea stellata* in alloxan-induced diabetic rats *Singapore Med J* 2008; 49(2): 137-141.
193. **Rang H.P., Dale M.M., Ritter J.M., Moore P.K., (2003):** Endocrine disorders. *Pharmacology*; 5 ed. 384-385
194. **Reaven G, Abbasi F and McLaughlin T., (2004):** Obesity, insulin resistance, and cardiovascular disease. *Recent Prog Horm Res.* ;59:207-23

References

195. **Renata Mikstacka & Agnes M. Rimando and Ewa Ignatowicz., (2010):** Antioxidant Effect of trans-Resveratrol, Pterostilbene, Quercetin and Their Combinations in Human Erythrocytes In Vitro *Plant Foods Hum Nutr* 65:57–63.
196. **Reusch, J. E. (2003):** Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose? *J.Clin.Invest* 112, 986-988.
197. **Rhee SG (2006):** Cell signaling. H₂O₂, a necessary evil for cell signaling. *Science (journal)* 312 (5782): 1882–3.

-
198. **Robert J, Nijveldt, Els van Nood, Danny EC van Hoorn, Petra G Boelens, Klaske van Norren, Paul AM and van Leeuwen., (2001):** Flavonoids: a review of probable mechanisms of action and potential applications¹ American Journal of Clinical Nutrition, Vol. 74, No. 4, 418-425.
199. **Robinson KM, Michael S, Janes MS, et al., (2006):** Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc Natl Acad Sci USA; 103: 15038-43.
200. **Rossini, A. A., Mordes, J. P., Greiner, D. L., and Stoff, J. S. (2001):** Islet cell transplantation tolerance. Transplantation 72, S43-S46.
201. **Roy S.S., et al. (2003):** A New Cell Secreting Insulin. Endocrinology, 144(4), 1585-1593.
202. **Ruano-Ravina A, Figueiras A, Freire-Garabal M, Barros-Dios JM (2006):** Antioxidant vitamins and risk of lung cancer. Curr. Pharm. Des. 12 (5): 599–613.
203. **Ruggeri ZM., (2002):** Platelets in atherosclerosis. Nat Med 8:1227–1234.
204. **Saltiel, A. R. & Olefsky, J. M. (1996):** Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669.
205. **Saltiel, A. R. (2001):** New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517-529.

206. **Saltiel, A. R., and Kahn, C. R. (2001):** Nature 414(6865), 799-806
207. **Samson M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA., (2000):** Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 278:G946–G951.
208. **Sasahara, M., Nishi, M., Kawashima, H., Ueda, K., Sakagashira, S., Furuta, H., Matsumoto, E., Hanabusa, T., Sasaki, H., & Nanjo, K. (2004).** Uncoupling protein 2 promoter polymorphism -866G/A affects its expression in beta-cells and modulates clinical profiles of Japanese type 2 diabetic patients. Diabetes 53, 482-485.
209. **Scoppola A, Montecchi FR, Menzinger G, Lala A., (2001):** Urinary mevalonate excretion rate in type 2 diabetes: role of metabolic control. Atherosclerosis; 156:357-61.
210. **Seino S., (2002):** Molecular mechanisms of insulin secretion. June 14-18; Diabetes, Volume 51, Supplement 2.
211. **Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R, (2001):** Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. Faseb J 15:2099-111.
212. **Shenouda NS, Zhou C, Browning JD, et al., (2004):** Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer; 49: 200–208.

-
213. **Shinji Kawahito, Hiroshi Kitahata and Shuzo Oshita., (2009):** Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress *World J Gastroenterol.* 15(33): 4137-4142.
214. **Shutenko Z, Henry Y, Pinard E, et al., (1999):** Influence of the antioxidant quercetin in vivo on the level of nitric oxide determined by electron paramagnetic resonance in rat brain during global ischemia and reperfusion. *Biochem Pharmacol*; 57:199–208.
215. **Sigal RJ, Kenny GP, Boulé NG, et al. (2007):** Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial". *Ann. Intern. Med.* 147 (6): 357–69.
216. **Solinas Giovanni, et al, (2007):** JNK1 in Hematopoietically Derived Cells Contributes to Diet-Induced Inflammation and Insulin Resistance without Affecting Obesity. *Cell Metabolism*, 6 (5): 386–397.
217. **Stadler K, Jenei V, von Bolcschazy G, Somogyi A, Jakus J.** Role of free radicals and reactive nitrogen species in the late complications of diabetes mellitus in rats. *Orv Hetil.* 2004;145:1135-1140
218. **Stephen L. Aronoff, MD, Kathy Berkowitz, Barb Shreiner and Laura Want, (2004):** Glucose metabolism and regulation: Beyond Insulin and Glucagon *Diabetes Spectrum* Volume 17, Number 3, Streptozotocin - induced oxidative stress and β -cell damage in rat pancreas *Pharmacological Research* 51 117–123.
219. **Stephen O. Adewole¹, Ezekiel A. Caxton-Martins and John A. O. Ojewole., (2007):** protective effect f Quercetin on the morphology of pancreatic B cells of streptozotocin treated diabetic rats. *African*
-

Journal of Traditional, Complimentary and Alternative Medicines,,
Vol.4, No. 1, , pg. 64-74

220. **SZKUDELSKI T, KANDULSKA K, OKULICZ M (1998):**
Alloxan in vivo does not only exert deleterious effects on pancreatic B
cells. *Physiol Res* **47**: 343-346, 1998.
221. **SZKUDELSKI., (2001):** The Mechanism of Alloxan and
Streptozotocin Action in B Cells of the Rat Pancreas
222. **Tanaka, P. O. T. Tran, J. Harmon, and R. P. Robertson.,
(2002):** A role of glutathione peroxidase in protecting pancreatic β
cells against oxidative stress in a model of glucose toxicity,”
*Proceedings of the National Academy of Sciences of the United States
of America*, vol. 99, pp. 12363–12368.
223. **Thiagalingam A, Nelkin BD, and Casero RA Jr, (2000):**
Reactive oxygen species are critical for the growth and differentiation
of medullary thyroid carcinoma cells. *Clin Cancer Res* **6**: 3783-3787.
224. **Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, (1977):** Relation
between antioxidant enzyme gene expression and antioxidative
defense status of insulin-producing cells, *Diabetes*, vol. 46, no. 11, pp.
1733–1742.
225. **Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H.,
(1998):** Effect of soybean phytoestrogen intake on low density
lipoprotein oxidation resistance. *Proc Natl Acad Sci U S A* **95**:3106–
3110.

-
226. **Tiwari, A.K., and J. Madhusudana Rao, (2002):** Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Curr Sci.*, 83: 30-38.
227. **Tiwari, A.K., and J. Madhusudana Rao, (2002):** Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Curr Sci.*, 83: 30-38.
228. **Valdez R. Epidemiology (2000):** *Nutr Rev*; 58:S4–S6
229. **Van Dam PS., (2002):** Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. *Diabetes Metab Res Rev.*; 18:176-184.
230. **Van der Woude, H., Boersma, M. G., Vervoort, J. and Rietjens, I. M. (2004):** Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems. *Chem. Res. Toxicol.* 17, 1520–1530.
231. **Van Erk MJ, Roepman P, van der Lende TR, and et al., (2005):** Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancerrelated mechanisms in colon cancer cells in vitro. *Eur J Nutr*; 44: 143–156.
232. **Van Gaal L, Mertens I, De Block C (2006):** Mechanisms linking obesity with cardiovascular disease. *Nature* 444 (7121): 875–80.
233. **Vertuani S, Angusti A, Manfredini S., (2004):** The antioxidants and pro-antioxidants network: an overview. *Curr Pharm Des* 10 (14): 1677–94.

-
234. **Vessal M, Hemmati M, Vasei M., (2003):** Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* Volume 135, Issue 3, 2003, Pages 357-364
235. **Vessal M, Hemmati M, Vasie M., (2003):** Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. *Comp Biochem Physiol Toxicol Pharmacol* ; 135: 357-64.
236. **Vignais PV., (2002):** The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. *Cell Mol Life Sci* 59:1428–1459, pmid: 12440767.
237. **Virkamaki, A., Korshennikova, E., Seppala-Lindroos, A., Vehkavaara, S., Goto, T., Halavaara, J., Hakkinen, A. M., and Yki-Jarvinen, H. (2001)** *Diabetes* 50(10), 2337-2343.
238. **Vitrac X, Desmouliere A, Brouillaud B, et al., (2003):** Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. *Life Sci*; 72:2219–33
239. **Wallum BJ, Kahn SE, McCulloch DK, Porte D, (1999):** Insulin secretion in the normal and diabetic human international Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. Chichester, U.K., John Wiley and Sons, p.285 –301.
240. **Wei, Y.H. and Lee, H.C. (2002):** Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. *Exp. Biol. Med.* (Maywood), 227, 671–682.

-
241. **Weyer C, Maggs DG, Young AA and Kolterman OG., (2001):** Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. *Curr Pharm Des* 7:1353–1373.
242. **Weyer, C., Bogardus, C., Mott, D. M. and Pratley, R. E. (1999):** The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J. Clin. Invest.*, 104: 787–794.
243. **Wiczowski, W., Romaszko, J.; Bucinski, A.; Szawara-Nowak, D.; Honke, J.; Zielinski, H.; Piskula, M.K., (2008):** Quercetin from shallots is more bioavailable than its glucosides. *J. Nutr.*, 138, 885–888.
244. **Williams JK and Clarkson TB., (1998):** Dietary soy isoflavones inhibit in-vivo constrictor responses of coronary arteries to collagen-induced platelet activation. *Coron Artery Dis* 9:759–764.
245. **Winer N and Sowers JR., (2007):** Diabetes and arterial stiffening. *Adv Cardiol.* ;44:245-251.
246. **Wolff SP, Jiang ZY and Hunt JV., (1991):** Protein glycation and oxidative stress in diabetes mellitus and ageing. *Free Radic Biol Med.* 10:339-35.
247. **Wood-Kaczmar A, Gandhi S, and Wood N (2006):** Understanding the molecular causes of Parkinson's disease. *Trends Mol Med* 12 (11): 521–8.
248. **Wulf Dröge., (2002):** Free Radicals in the Physiological Control of Cell Function *Physiol. Rev.* 82: 47-95; 0031-9333/02.
-

-
249. **Yamagishi S, and Imaizumi T., (2005):** Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. *Curr Pharm Des.* 11:2279-2299.
250. **Yamaguchi, Y., Flier, J. S., Yokota, A., Benecke, H., Backer, J. M., and Moller, D. E. (1991):** *Endocrinology* 129, 2058-2066
251. **Yamamoto Y and Oue E., (2006):** Antihypertensive effect of quercetin in rats fed with a high-fat, high-sucrose diet. *Biosci Biotechnol Biochem*; 70(4):933-9.
252. **Yip CC, Ottensmeyer P, (2003):** Three-dimensional structural interactions of insulin and its receptor. *J Biol Chem.* , 278:27329-27332.
253. **Youdim KA, Martin A and Joseph JA., (2000):** Incorporation of the elderberry anthocyanins by endothelial cells increases protection against oxidative stress. *Free Radic Biol Med*; 29:51–60
254. **Young IS and J. McEneny (2001):** Lipoprotein oxidation and atherosclerosis. *Biochemical Society Transactions* 29: 358-362.
255. **Youngren, J. F., Manchem, V. P., Kozlowski, M., Zhang, B. B., Maddux, B. A., and Goldfine, I. D. (2001):** *Diabetes* 50(10), 2323-2328
256. **Zhang HN and Lin ZB (2004):** Hypoglycemic effect of *Ganoderma lucidum* polysaccharides, *Acta Pharmacol. Sin* 25 (2): 191–5.

257. **Zhang Y, Hendrich S and Murphy PA., (2003):** Glucuronides are the main isoflavone metabolites in women. *J Nutr* 2003; 133:399–404.
258. **Zhu BT, Ezell ETand Liehr JG., (2001):** Catechol-o-methyl transferase catalysis rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. *J Biol Chem*; 269:292–9.
259. **Zorov DB, Filburn CR, Klotz LO, Zweier JL, and Sollott SJ., (2000):** Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J Exp Med*; 192: 1001.